Get to know our clinical trials
Clinical trial of lebrikizumab compared to placebo in participants aged 6 months to less than 18 years with moderate to severe atopic dermatitis
THE MAIN REASON FOR THIS STUDY IS TO TRY TO FIND AN ANSWER TO THE FOLLOWING SCIENTIFIC QUESTIONS: - THE EFFICACY AND SAFETY OF LEBRIKIZUMAB. - WHETHER ADMINISTRATION OF LEBRIKIZUMAB WITH TOPICAL CORTICOSTEROIDS (TC) CAN HELP STUDY PARTICIPANTS WITH AD, COMPARED TO ADMINISTRATION OF A PLACEBO AND TC.
Technical Summary
- PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS AGED 6 MONTHS TO LESS THAN 18 YEARS WITH MODERATE TO SEVERE ATOPIC DERMATITIS. IMMUNOTHERAPY
- Code EudraCT: 2022-501476-25-00
- Protocol number: J2T-MC-KGBI
- Promoter: Lilly
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.